ReviewDrugs & aging2019
Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications.
Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Systematic review of influenza vaccine effectiveness against laboratory-confirmed influenza among older adults living in aged care facilities.Human vaccines & immunotherapeutics · 2023Pooled it
- Adult Vaccination as a Protective Factor for Dementia: A Meta-Analysis and Systematic Review of Population-Based Observational Studies.Frontiers in immunology · 2022Pooled it
- Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness.Human vaccines & immunotherapeutics · 2020Pooled it
- Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial.Nature communications · 2024Trial
- The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.Influenza and other respiratory viruses · 2024Trial
- Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.Human vaccines & immunotherapeutics · 2022Trial
- Travel vaccination in senior travelers: current evidence, challenges, and prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Article
- Developing a Latin American Delphi Consensus on Vaccination for Respiratory Diseases in Older Adults.Annals of geriatric medicine and research · 2025Article
- Rapid aging of influenza epidemics in China from 2005/06 to 2016/17: A population-based study.Infectious Disease Modelling · 2025Article
- Influenza: temporal trends in mortality, hospitalization, and vaccination in the older adults population aged 60 and more years, Brazil, 2000-2023.Frontiers in public health · 2025Article
- Controlled Human Infection Challenge Studies with RSV.Current topics in microbiology and immunology · 2024Review
- Vaccination and Therapeutics.Advances in experimental medicine and biology · 2024Review
- Review
- Immunology of Aging: the Birth of Inflammaging.Clinical reviews in allergy & immunology · 2023Review
- Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data.The journal of nutrition, health & aging · 2023Article
- COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.The lancet. Healthy longevity · 2022Article
- COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.Clinics in geriatric medicine · 2022Review
- Reanalysis of a Randomized Controlled Trial on Promoting Influenza Vaccination in General Practice Waiting Rooms: A Zelen Design.Vaccines · 2022Article
- Moving beyond Titers.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza can lead to serious illness, particularly for older adults. In addition to short-term morbidity and mortality during the acute infection, recovery can be prolonged and often incomplete. This may lead to persistent declines in health and function, including catastrophic disability, which has dramatic implications for the well-being and support needs of older adults and their caregivers. All of this means that prevention of infection and effective treatment when illness has occurred are of paramount importance. In this narrative review, we discuss the effectiveness of influenza vaccines for the prevention of influenza illness and serious outcomes in older adults. We review evidence of vaccine effectiveness for older adults in comparison with younger age groups, and also highlight the importance of frailty as a determinant of vaccine effectiveness. We then turn our attention to the question of why older and frailer individuals have poorer vaccine responses, and consider changes in immune function and inflammatory responses. This sets the stage for a discussion of newer influenza vaccine products that have been developed with the aim of enhancing vaccine effectiveness in older adults. We review the available evidence on vaccine efficacy, effectiveness and cost benefits, consider the potential place of these innovations in clinical geriatric practice, and discuss international advisory committee recommendations on influenza vaccination in older adults. Finally, we highlight the importance of influenza prevention to support healthy aging, along with the need to improve vaccine coverage rates using available vaccine products, and to spur development of better influenza vaccines for older adults in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.